The 2022 update on the pipeline of Parkinsons drug therapies in the clinical trial

content.iospress.com/articl...

[hanoverdr]

I appreciate your adding this reference and seeing the number of remedies in Phase 3 especially. Also it's good to know there are studies for drugs to address the disease directly, even though there are fewer than those that address symptoms.

[Hidden]

twitter.com/grafaloff/statu...

[Hidden]

any idea why Zhittya is not on this list?

[WinnieThePoo]

No recognised clinical trial registered would be the bookies favourite for why they're not on the list . Don't get me wrong, the thing I love about zhittya is their sense of urgency (although with their new trial, inspired by snorting lines of coke possibly, of fgf-1 intra-nasal in the Caribbean, they appear to have forgotten about the intravenous Mexican trial which is now 2 years behind schedule)

But it's "piss or get off the pot" for zhittya. We'll have a really strong indication whether this is the real deal or not this year.

Which is why, with 2 people dosed at half strength, and neither of them dead yet, they are in a hurry to hit the venture capital investor trail for which this webinar is the prelude

They may lack any conventional scientific rigour but I have been saying privately to a couple of mates, I think they may just have stumbled on something

You can't beat a bit of serendipity.

Mind you. Even if there is a strong indication that it works don't count on it being available any time soon. They have committed all of their stock of fgf-1 from 2 years manufacturing and it's enough for 300 people